Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M (NASDAQ:IMDX)May 14, 2026
Share Facebook Twitter LinkedIn Pinterest Email Bristol Myers names incoming top boss Christopher Boerner as board chair
Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M (NASDAQ:IMDX)May 14, 2026
Eos reaffirms $300M-$400M 2026 revenue outlook while outlining Frontier Power USA $150M rights offering plan (NASDAQ:EOSE)May 13, 2026
